Tiziana’s Intranasal Foralumab Trial for MSA Gains Spotlight at World Parkinson Congress
Event summary
- Tiziana’s Phase 2a trial of intranasal foralumab for Multiple System Atrophy (MSA) will be presented as a late-breaking poster at the 7th World Parkinson Congress (May 24-27, 2026).
- The open-label TILS-025 trial (NCT06868628) is enrolling up to 10 MSA patients, with primary endpoints measuring microglial activation via [F-18]PBR06 TSPO PET imaging and MDS-UMSARS scores.
- Foralumab, a fully human anti-CD3 monoclonal antibody, has shown promise in reducing neuroinflammation in prior studies for MS and Alzheimer’s disease.
The big picture
Tiziana’s focus on neuroinflammation via intranasal foralumab aligns with growing interest in targeting microglial activation in neurodegenerative diseases. The acceptance of its MSA trial data at the World Parkinson Congress underscores the field’s urgency for novel therapies, particularly in rare, rapidly progressive conditions like MSA. The company’s ability to leverage its nasal delivery platform could position it as a key player in neuroimmunology, provided clinical validation continues.
What we're watching
- Clinical Efficacy
- Whether intranasal foralumab can demonstrate meaningful attenuation of microglial activation in MSA patients, a critical step toward validating its disease-modifying potential.
- Regulatory Pathway
- The pace at which Tiziana can advance foralumab through later-stage trials, given the high unmet need in MSA and the lack of approved therapies.
- Competitive Positioning
- How Tiziana’s intranasal delivery approach differentiates it from traditional IV-administered anti-CD3 therapies in neuroinflammatory diseases.
Related topics